Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Neoplasms × parsaclisib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 322 Trastuzumab 306 Paclitaxel 272 Docetaxel 242 Capecitabine 208 Letrozole 196 Doxorubicin 165 Carboplatin 162 Tamoxifen 142 Radiotherapy 142 Fulvestrant 132 Epirubicin 125 Anastrozole 121 Surveys and Questionnaires 118 Exercise 111 Vinorelbine 104 palbociclib 96 exemestane 94 Blood Specimen Collection 94 Bevacizumab 93 Magnetic Resonance Spectroscopy 92 pertuzumab 88 pembrolizumab 88 Albumin-Bound Paclitaxel 79 Gemcitabine 76 Drug Therapy 70 Lapatinib 69 Cisplatin 63 Biopsy 63 130-nm albumin-bound paclitaxel 63

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04142554 2020-11-03

LCCC1820

UNC Lineberger Comprehensive Cancer Center

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡